Comparative Pharmacology
Head-to-head clinical analysis: TECENTRIQ versus XTANDI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECENTRIQ versus XTANDI.
TECENTRIQ vs XTANDI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atezolizumab is a humanized monoclonal IgG1 antibody that binds to PD-L1, blocking its interaction with PD-1 and CD80 receptors, thereby reversing PD-L1-mediated inhibition of T-cell activation and restoring anti-tumor immune responses.
Androgen receptor inhibitor; binds to the androgen receptor, inhibits nuclear translocation, DNA binding, and transcription of androgen-responsive genes.
800 mg intravenously every 2 weeks; or 1200 mg intravenously every 3 weeks; or 1680 mg intravenously every 4 weeks.
160 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 27 days (range: 20–35 days). This long half-life supports every-3-week dosing and reflects slow clearance typical of IgG1 antibodies.
Enzalutamide: 5.8 days; active metabolite N-desmethyl enzalutamide: 7.8-8.6 days. Steady state achieved after ~28 days.
Tecentriq (atezolizumab) is a monoclonal antibody; elimination occurs via intracellular catabolism into amino acids. No renal or biliary/fecal excretion of intact drug. 0% unchanged in urine or feces.
Primarily hepatic metabolism; 77% of dose recovered in feces (as metabolites), 15% in urine (as metabolites); less than 1% excreted unchanged.
Category C
Category C
Antineoplastic, PD-L1 Inhibitor
Antineoplastic